Stockreport

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

Nuvectis Pharma, Inc.  (NVCT) 
PDF Precision oncology player Nuvectis Pharma receives a buy recommendation and price target with a significant premium from Lucid Capital Markets. Report highlights Nuvecti [Read more]